To determine the dose and schedule of sirolimus when given in combination with panitumumab in adult subjects with Stage IIIB/IV NSCLC

Inclusion Criteria:

• Histologically- or cytologically-confirmed diagnosis of stage IIIB or IV Non-Small Cell Lung Cancer
• Received only one prior treatment (not including radiation)
• Measurable disease per Response Evaluation Criteria in Solid Tumors Group (RECIST) guidelines
• Life expectancy of ≥ 4 months
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Adequate hematologic, renal and hepatic function
• Serum-fasting cholesterol ≤ 300 mg/dL Serum-fasting triglycerides ≤ 2.5 X ULN Exclusion Criteria:
• Brain metastases requiring treatment
• History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline
• Systemic chemotherapy, radiotherapy, hormonal therapy or immunotherapy within 30 days before enrollment
• Prior epidermal growth factor receptor targeting agents with the exception of the small molecule EGFr tyrosine kinase inhibitors
• Prior anti-tumor therapies including prior experimental agents or approved anti-tumor small molecules and biologics of short serum half-life (less than 1 week) within 30 days before enrollment, or prior experimental or approved proteins/antibodies with longer serum half-life within 6 weeks before enrollment
• Prior therapy with sirolimus, sirolimus analogs
• Immunosuppressive agents within 28 days before enrollment